Real Clinical Experience with Great Outcome in Guselkumab Injection (Tremfya) Treatment in Psoriatic patients, A retrospective Study

Abstract

Iman Mohamed Almasry, Hisham Hanfi, Nadia Alnaki, Sara Muslem, Hassan Ash-kinin, Amna Alsaeedi and Atlal Alallfi

Introduction Psoriasis is a chronic inflammatory disease. Current time many biologicals are available which gives a wide range of therapeutic options for psoriatic patients. Guselkumab is one of the earliest IL-23p19 inhibitors approved for psoriasis treatment with high efficacy and proven safety.

Material and Methods This retrospective study analyzed data from the electronic medical record system of As’ad Al-Hamad Dermatology Center Sabah hospital Kuwait. We collected relevant demographic data and clinical features of all patients on Guselkumab injection from January 2022 to December 2024.

Results This study ultimately included a total 43 patients with psoriasis on Guselkumab therapy. The median age was 45.0 years (IQR 40.0-56.5), with 46.5% (n=20) male patients. Treatment effectiveness was very high as PASI90 and PASI100 were achieved in 97.7% (n=42) and 76.7% (n=33) of patients, respectively. PASI90 was typically reached early median dose 1, while PASI100 was achieved by a median of dose 2. It showed no significant baseline differences between patients with and without prior biologic exposure, except for higher baseline PASI in biologic-naïve patients (43.3 ± 12.6 vs 26.9 ± 8.8, p < 0.001) and PASI100 achievement was significantly lower in biologic-experienced patients. Regard safety the adverse events were reported in 25.6% (n=11) of patients, predominantly mild injection-site pain in 16.3% (n=7). Infection-related events were infrequent, occurring in 9.3% (n=4), with isolated cases of urinary tract infection (2.3%, n=1), cellulitis (2.3%, n=1), impetigo (2.3%, n=1), and upper respiratory infection (2.3%, n=1).

Conclusions Interleukin (IL)-23p19 inhibitors guselkumab demonstrated a significant maintained effectiveness for psoriasis treatment. In addition, a high safety profile regardless comorbidities, and treatment was not discontinued due to any adverse effects complications.

PDF